AITRICS Unveils Six Clinical Study Results, Including Prospective and Real-World Data Studies

Building on Last Year’s FDA Clearance to Establish a Foundation for Expansion into the U.S. Market

AITRICS (CEO Kwang joon Kim) announced on March 10 that it participated in the 2025 HIMSS Global Health Conference & Exhibition (HIMSS 2025), held in Las Vegas, USA, from March 3 to 6.

The HIMSS Global Health Conference & Exhibition is the world’s largest and most prestigious international event in healthcare information and communication technology, organized by the Healthcare Information and Management Systems Society (HIMSS).

At this exhibition, AITRICS showcased its AI-powered patient deterioration prediction solution, AITRICS-VC (VitalCare). The company highlighted the product’s ability to predict the risk of various conditions, including sepsis and mortality, at an early stage—making it the first solution of its kind in Korea. Additionally, AITRICS presented six clinical study results, including prospective studies and real-world data research, emphasizing the strong clinical efficacy of VitalCare accumulated in Korea.

The company also garnered significant interest from global medical institutions following its FDA 510(k) clearance last year, fostering discussions with healthcare professionals to advance additional joint research initiatives.

Kwang joon Kim, CEO of AITRICS, stated, “With VitalCare recently receiving FDA clearance, HIMSS 2025 provided an excellent opportunity to effectively showcase the product’s excellence in the U.S. market and take a significant step toward our expansion efforts. Moving beyond Korea, we aim to introduce the clinical efficacy of VitalCare to the global medical field and actively engage in collaborations with U.S. healthcare institutions to accelerate our global market entry.”

Currently, AITRICS’ VitalCare is actively deployed in over 90 hospitals across Korea.